Article
Pharmaceutical Executive
Is Pfizer Ready for Another Acquisition?
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover?
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
